



June 2007

NEW DIRECTOR FOR NORGINE REGULATORY AFFAIRS

Dr Maria Tomás has been appointed as Norgine's Director of Regulatory Development.

She joins Norgine from GlaxoSmithKline and will be responsible for all new products in clinical development and variations to existing products, including new formulations and indications.

Dr Tomás has spent 14 years in regulatory affairs and project management and has a Diploma in Regulatory Affairs, PhD in Biochemistry, MSc in Toxicology and a first degree in Pharmacy.

ENDS

Notes to editor

Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a presence in all the major European markets. In 2006 Norgine's sales were €188 million, the 20th consecutive year of double-digit growth. The company employs over 1000 people, of whom 350 are in sales and marketing.

Norgine's current focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g. MOVICOL® for the treatment of chronic constipation and faecal impaction, MOVIPREP® a new generation bowel cleansing preparation, KLEAN-PREP® for bowel preparation prior to colonoscopy, and ORAMORPH® for the treatment of moderate to severe pain associated with cancer.

Norgine has an active Research and Development effort and currently has products at various stages of clinical development. Norgine has two manufacturing sites; Hengoed in the UK and Dreux, France.

Norgine's website is www.norgine.com

For further information, please contact:

Paul Pay, Vice-President, Business Development, Norgine

T: +44 (0)1895 453710

E: ppay@norgine.com

Louise Blakeborough, Chapter Five

T: +44 (0)1306 731800

E: lblakeborough@chapterfive.co.uk